<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">eLife</journal-id><journal-id journal-id-type="iso-abbrev">Elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7311167</article-id><article-id pub-id-type="publisher-id">57877</article-id><article-id pub-id-type="doi">10.7554/eLife.57877</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization</article-title></title-group><contrib-group><contrib id="author-141145" contrib-type="author" corresp="yes"><name><surname>Klasse</surname><given-names>PJ</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8222-278X</contrib-id><email>pek2003@med.cornell.edu</email><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib id="author-101858" contrib-type="author"><name><surname>Moore</surname><given-names>John P</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution>Department of Microbiology and Immunology, Weill Cornell Medicine</institution><addr-line>New York</addr-line><country>United States</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Giamarellos-Bourboulis</surname><given-names>Evangelos J</given-names></name><role>Reviewing Editor</role><aff><institution>Attikon University Hospital</institution><country>Greece</country></aff></contrib><contrib contrib-type="editor"><name><surname>van der Meer</surname><given-names>Jos WM</given-names></name><role>Senior Editor</role><aff><institution>Radboud University Medical Centre</institution><country>Netherlands</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>23</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e57877</elocation-id><history><date date-type="received" iso-8601-date="2020-04-20"><day>20</day><month>4</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-06-05"><day>05</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020, Klasse and Moore</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Klasse and Moore</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-57877.pdf"/><abstract><p>We review aspects of the antibody response to SARS-CoV-2, the causative agent of the COVID-19 pandemic. The topics we cover are relevant to immunotherapy with plasma from recovered patients, monoclonal antibodies against the viral S-protein, and soluble forms of the receptor for the virus, angiotensin converting enzyme 2. The development of vaccines against SARS-CoV-2, an essential public health tool, will also be informed by an understanding of the antibody response in infected patients. Although virus-neutralizing antibodies are likely to protect, antibodies could potentially trigger immunopathogenic events in SARS-CoV-2-infected patients or enhance infection. An awareness of these possibilities may benefit clinicians and the developers of antibody-based therapies and vaccines.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>antibodies</kwd><kwd>vaccine</kwd><kwd>plasma</kwd><kwd>therapy</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 AI36082</award-id><principal-award-recipient><name><surname>Moore</surname><given-names>John</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01 AI110657</award-id><principal-award-recipient><name><surname>Moore</surname><given-names>John</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>OPP1132237</award-id><principal-award-recipient><name><surname>Moore</surname><given-names>John</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>INV-002022</award-id><principal-award-recipient><name><surname>Moore</surname><given-names>John</given-names></name></principal-award-recipient></award-group><funding-statement>The authors declare that the funders had no role in study design, data collection or interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Antibodies hold promise for breakthrough treatment of COVID-19, the disease caused by the coronavirus SARS-CoV-2.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Passive immunization with plasma from patients who have seroconverted to and recovered from infection with a pathogen has a long and generally successful history. It has been used extensively against influenza virus and on a small scale during the 1995 and 2014&#x02013;2015 Ebola epidemics (<xref rid="bib12" ref-type="bibr">Brown et al., 2018</xref>; <xref rid="bib53" ref-type="bibr">Mupapa et al., 1999</xref>; <xref rid="bib51" ref-type="bibr">Mair-Jenkins et al., 2015</xref>; <xref rid="bib38" ref-type="bibr">Hung et al., 2011</xref>; <xref rid="bib50" ref-type="bibr">Luke et al., 2006</xref>). Purified polyclonal (sometimes referred to as polyvalent) immunoglobulin (Ig) from convalescents has been administered prophylactically after exposure to infectious virus (<xref rid="bib81" ref-type="bibr">Young, 2019</xref>). In recent years, highly specific and often broadly active neutralizing monoclonal antibodies (MAbs) have been developed against several viruses, as a more advanced substitute for patient plasma (<xref rid="bib15" ref-type="bibr">Caskey et al., 2019</xref>; <xref rid="bib19" ref-type="bibr">Corti et al., 2016</xref>; <xref rid="bib20" ref-type="bibr">Corti et al., 2017</xref>; <xref rid="bib71" ref-type="bibr">Walker and Burton, 2018</xref>; <xref rid="bib76" ref-type="bibr">Wec et al., 2019</xref>; <xref rid="bib84" ref-type="bibr">Zheng et al., 2020</xref>). These methods are now being considered for treating COVID-19, the disease caused by the SARS-CoV-2 coronavirus (<xref rid="bib23" ref-type="bibr">Dhama et al., 2020</xref>; <xref rid="bib42" ref-type="bibr">Jawhara, 2020</xref>; <xref rid="bib43" ref-type="bibr">Ju et al., 2020</xref>; <xref rid="bib85" ref-type="bibr">Zhou and Zhao, 2020</xref>; <xref rid="bib1" ref-type="bibr">Accorsi et al., 2020</xref>; <xref rid="bib9" ref-type="bibr">Bloch et al., 2020</xref>; <xref rid="bib64" ref-type="bibr">Sullivan and Roback, 2020</xref>). Several reports describe apparent benefits, with no adverse side effects, when convalescent plasma was infused into patients with SARS-CoV-1 or SARS-CoV-2 infection (<xref rid="table1" ref-type="table">Table 1</xref>; <xref rid="bib17" ref-type="bibr">Cheng et al., 2005</xref>; <xref rid="bib80" ref-type="bibr">Yeh et al., 2005</xref>; <xref rid="bib62" ref-type="bibr">Soo et al., 2004</xref>; <xref rid="bib60" ref-type="bibr">Shen et al., 2020</xref>; <xref rid="bib29" ref-type="bibr">Duan et al., 2020</xref>; <xref rid="bib83" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="bib3" ref-type="bibr">Ahn et al., 2020</xref>). The US Food and Drug Administration has recently approved plasma immunotherapy for this purpose, and has outlined safety criteria (<ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma">https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma</ext-link>). To determine the efficacy of convalescent plasma to treat COVID-19, the FDA has called for randomized clinical trials and encouraged investigational new drug applications (<xref rid="bib9" ref-type="bibr">Bloch et al., 2020</xref>; <xref rid="bib64" ref-type="bibr">Sullivan and Roback, 2020</xref>). Here, we review aspects of the antibody response to SARS-CoV-2, which may be relevant to immunotherapy with plasma or MAbs. A major goal of viral vaccine development is the induction of strong and broadly active neutralizing antibodies (NAbs), and that goal applies also to SARS-CoV-2 (<xref rid="bib23" ref-type="bibr">Dhama et al., 2020</xref>; <xref rid="bib32" ref-type="bibr">Graham, 2020</xref>; <xref rid="bib6" ref-type="bibr">Amanat and Krammer, 2020</xref>). The development of vaccines, an essential public health tool, will also be informed by an understanding of the antibody response during SARS-CoV-2 infection.</p><table-wrap id="table1" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Passive immunization with convalescent plasma (CP) during SARS-CoV-1 and SARS-CoV-2 infection.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" rowspan="1" colspan="1">Reference</th><th valign="top" rowspan="1" colspan="1">Virus</th><th valign="top" rowspan="1" colspan="1">Antibody source</th><th valign="top" rowspan="1" colspan="1">Number of patients</th><th valign="top" rowspan="1" colspan="1">Efficacy</th><th valign="top" rowspan="1" colspan="1">Safety</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1"><break/><xref rid="bib17" ref-type="bibr">Cheng et al., 2005</xref></td><td valign="top" rowspan="1" colspan="1">SARS-CoV-1</td><td valign="top" rowspan="1" colspan="1">CP <break/>160&#x02013;640 ml <break/>Seropositive titer range: <break/>160&#x02013;2,560</td><td valign="top" rowspan="1" colspan="1">80 patients with SARS</td><td valign="top" rowspan="1" colspan="1">Better outcome with plasma before than after day 14</td><td valign="top" rowspan="1" colspan="1">No immediate adverse effects</td></tr><tr><td valign="top" rowspan="1" colspan="1"><break/><xref rid="bib80" ref-type="bibr">Yeh et al., 2005</xref></td><td valign="top" rowspan="1" colspan="1">SARS-CoV-1</td><td valign="top" rowspan="1" colspan="1">CP <break/>500 ml <break/>IF IgG titer <break/>&#x0003e;640</td><td valign="top" rowspan="1" colspan="1">3 hospital workers with SARS</td><td valign="top" rowspan="1" colspan="1">Drop within 24 hr in viral load from ~ 10<sup>5</sup> to &#x0003c; 1 RNA copies/ml</td><td valign="top" rowspan="1" colspan="1">No significant side effects</td></tr><tr><td valign="top" rowspan="1" colspan="1"><break/><xref rid="bib62" ref-type="bibr">Soo et al., 2004</xref></td><td valign="top" rowspan="1" colspan="1">SARS-CoV-1</td><td valign="top" rowspan="1" colspan="1">CP <break/>Ab titers not measured</td><td valign="top" rowspan="1" colspan="1">19 (plasma) vs. 21 (methylprednisolone) SARS patients</td><td valign="top" rowspan="1" colspan="1">Faster release, lower mortality with plasma than comparator</td><td valign="top" rowspan="1" colspan="1">No immediate adverse effects</td></tr><tr><td valign="top" rowspan="1" colspan="1"><break/><xref rid="bib60" ref-type="bibr">Shen et al., 2020</xref></td><td valign="top" rowspan="1" colspan="1">SARS-CoV-2</td><td valign="top" rowspan="1" colspan="1">CP 400 ml <break/>Ab binding <break/>&#x0003e;1000 <break/>NAb&#x000a0;&#x0003e;&#x000a0;40</td><td valign="top" rowspan="1" colspan="1">5 COVID-19 patients</td><td valign="top" rowspan="1" colspan="1">Reduced viral load, clinical improvement Release of 3/5</td><td valign="top" rowspan="1" colspan="1">None reported</td></tr><tr><td valign="top" rowspan="1" colspan="1"><break/><xref rid="bib29" ref-type="bibr">Duan et al., 2020</xref></td><td valign="top" rowspan="1" colspan="1">SARS-CoV-2</td><td valign="top" rowspan="1" colspan="1">CP 200 ml <break/>NAb&#x000a0;&#x0003e;&#x000a0;640</td><td valign="top" rowspan="1" colspan="1">10 COVID-19 patients</td><td valign="top" rowspan="1" colspan="1">Virus undetectable in 7/10 <break/>Varying clinical, laboratory, radiological improvements</td><td valign="top" rowspan="1" colspan="1">No adverse effects observed</td></tr><tr><td valign="top" rowspan="1" colspan="1"><break/><xref rid="bib83" ref-type="bibr">Zhang et al., 2020</xref></td><td valign="top" rowspan="1" colspan="1">SARS-CoV-2</td><td valign="top" rowspan="1" colspan="1">CP 200&#x02013;2,400 ml <break/>Ab not measured</td><td valign="top" rowspan="1" colspan="1">4 COVID-19 patients</td><td valign="top" rowspan="1" colspan="1">Negative PCR <break/>Pulmonological improvements <break/>Discharge of 3/4</td><td valign="top" rowspan="1" colspan="1">No adverse effects observed</td></tr><tr><td valign="top" rowspan="1" colspan="1"><break/><xref rid="bib3" ref-type="bibr">Ahn et al., 2020</xref></td><td valign="top" rowspan="1" colspan="1">SARS-CoV-2</td><td valign="top" rowspan="1" colspan="1">CP 2 &#x000d7; 250 ml <break/>Binding IgG detected by ELISA</td><td valign="top" rowspan="1" colspan="1">2 COVID-19 patients</td><td valign="top" rowspan="1" colspan="1">Reduced sputum&#x000a0;viral&#x000a0;load Radiological and clinical improvements</td><td valign="top" rowspan="1" colspan="1">No adverse effects observed</td></tr></tbody></table></table-wrap><p>Assays are now available for detecting IgA, IgM, and IgG specific for SARS-CoV-2 in patient serum, that&#x000a0;is to demonstrate seroconversion, and also for detecting NAbs (<xref rid="bib5" ref-type="bibr">Amanat et al., 2020</xref>; <xref rid="bib79" ref-type="bibr">Wu et al., 2020</xref>). These techniques are rapidly evolving, and additional information on the antibody response to CoV-2 infection is emerging almost daily. Analyses of how long predictably protective titers are maintained are still lacking. They will be a priority once enough time has elapsed to allow long-term studies.</p><p>The natural history of COVID-19 and some lessons from infections with the previous SARS coronavirus (SARS-CoV-1) and the more distantly related MERS-CoV, including animal model studies, do raise some concerns about NAb-based therapies and vaccines, warranting careful surveillance by clinicians during human trials. Furthermore, certain approaches may minimize risks while preserving the benefits of passive immunization for curing COVID-19.</p><sec id="s1-1"><title>Antibody-mediated neutralization of SARS-CoV-2</title><p>The entry of SARS-CoV-2 into cells is initiated by the interaction of the receptor-binding domain (RBD) of the viral Spike (S) glycoprotein with the angiotensin converting enzyme-2 (ACE2), which acts as a receptor for the virus on the target cell surface (<xref rid="bib36" ref-type="bibr">Hoffmann et al., 2020</xref>; <xref rid="bib55" ref-type="bibr">Ou et al., 2020</xref>). The most potent NAbs are directed to the RBD and some may act by simply competing with the receptor for binding to the S-protein. Antibodies to SARS-CoV-1 and MERS-CoV generally do not cross-neutralize SARS-CoV-2; although cross-reactive antibodies are frequently detected in S-protein ELISA (<xref rid="bib43" ref-type="bibr">Ju et al., 2020</xref>; <xref rid="bib79" ref-type="bibr">Wu et al., 2020</xref>; <xref rid="bib55" ref-type="bibr">Ou et al., 2020</xref>; <xref rid="bib16" ref-type="bibr">Chen et al., 2005</xref>; <xref rid="bib59" ref-type="bibr">Quinlan et al., 2020</xref>; <xref rid="bib78" ref-type="bibr">Wrapp et al., 2020</xref>). Recently, however, the S-protein-specific NAb S309, isolated from memory B cells of a patient who had recovered from CoV-1 infection in 2003, was shown to neutralize both SARS-CoV-1 and &#x02212;2 potently by ligating the RBD. Cryo-electron microscopy and binding assays demonstrated that the conserved S309 epitope comprises glycans and that in spite of the specificity of the Mab for the RBD, it does not interfere with ACE2 binding (<xref rid="bib58" ref-type="bibr">Pinto et al., 2020</xref>).</p><p>The neutralizing potency of antibodies against the RBD may be determined not only by their own affinity for the S-protein but also by the affinity of the latter for ACE2, at least when they act by a competitive mechanism (<xref rid="bib43" ref-type="bibr">Ju et al., 2020</xref>). In this context, it is notable that the SARS-CoV-2 S-protein has a 4&#x02013;20-fold higher affinity for ACE2 than its counterpart from SARS-CoV-1 (35, 37). Although most NAbs to SARS-CoV-1 and &#x02212;2 are directed to the RBD (<xref rid="bib58" ref-type="bibr">Pinto et al., 2020</xref>; <xref rid="bib21" ref-type="bibr">Coughlin et al., 2007</xref>; <xref rid="bib33" ref-type="bibr">Greenough et al., 2005</xref>; <xref rid="bib63" ref-type="bibr">Sui et al., 2004</xref>; <xref rid="bib65" ref-type="bibr">ter Meulen et al., 2006</xref>; <xref rid="bib69" ref-type="bibr">van den Brink et al., 2005</xref>; <xref rid="bib86" ref-type="bibr">Zhu et al., 2007</xref>), some antibodies that recognize the SARS-CoV-1 S2 fragment can also neutralize (<xref rid="bib28" ref-type="bibr">Duan et al., 2005</xref>; <xref rid="bib30" ref-type="bibr">Elshabrawy et al., 2012</xref>). In addition, antibodies to the ectodomain of another surface-exposed SARS-CoV-1 protein, Orf3a, are also reported to have neutralizing activity, while antibodies to the M and E proteins can potentiate neutralization (<xref rid="bib4" ref-type="bibr">Akerstr&#x000f6;m et al., 2006</xref>; <xref rid="bib13" ref-type="bibr">Buchholz et al., 2004</xref>). Whether SARS-CoV-2 is similar to SARS-CoV-1 in all these respects remains to be determined. Nonetheless, passive and active immunization approaches to COVID-19 are generally focused on NAbs against the S1-protein.</p></sec><sec id="s1-2"><title>The kinetics of NAb and other antibody responses in SARS-CoV infection</title><p>The information on the antibody responses elicited in COVID-19 patients is growing fast, but none is yet available about the longevity of the immunity. Data on SARS-CoV-1 infection may, however, be informative in that respect. Surprisingly, the NAb response in patients who later succumbed to the infection has been found to be faster than in those who recovered; in the patients who later died, the titers had peaked around day 15 after the onset of symptoms, whereas similar titers and extents of neutralization were reached only after day 20 in the patients who recovered (<xref rid="bib82" ref-type="bibr">Zhang et al., 2006</xref>; <xref rid="bib35" ref-type="bibr">Ho et al., 2005</xref>). The NAb titers in the moribund patients declined or disappeared after the early rise, as their conditions deteriorated towards death (<xref rid="bib82" ref-type="bibr">Zhang et al., 2006</xref>). It is unknown whether this titer loss reflects an inability to produce antibodies due to lymphocyte losses. As NAb titers rise, however, viral loads decline, presumably because virus replication diminishes (<xref rid="bib77" ref-type="bibr">W&#x000f6;lfel et al., 2020</xref>; <xref rid="bib67" ref-type="bibr">To et al., 2020</xref>). These findings do not exclude the possibility that the initial viral loads, before NAbs emerged, were particularly high and stimulated stronger and earlier antibody responses in the patients who subsequently became most severely affected.</p><p>In plasma collected from 175 patients who had recovered from mild COVID-19, NAb and S-binding-antibody titers correlated positively with age and CRP (C-reactive protein) levels, but negatively with lymphocyte counts; and the NAbs did not cross-neutralize SARS-CoV-1 (<xref rid="bib79" ref-type="bibr">Wu et al., 2020</xref>). Since no severe cases were included and viral loads were not monitored, it is unclear what promoted the NAb responses within the patient cohort in which antibody titers, age (range 16&#x02013;85 years), lymphopenia, and inflammation were associated. The positive correlation between NAb responses and age contrasts with a general decline in the vigor of new B-cell responses in the elderly (<xref rid="bib61" ref-type="bibr">Siegrist and Aspinall, 2009</xref>), but raises the question whether the pre-response viral load was correlated with age, which in turn correlates with disease severity. Other studies have shown higher binding-antibody titers to the nucleocapsid protein N in patients who recovered than in those who did not (<xref rid="bib79" ref-type="bibr">Wu et al., 2020</xref>; <xref rid="bib48" ref-type="bibr">Leung et al., 2004</xref>). Such antibodies to the N-protein, which is internal and thus not exposed on the surface of the virion, completely lack neutralizing capacity but their production might reflect the strength of T-helper cell responses (<xref rid="bib45" ref-type="bibr">Klasse et al., 2012</xref>).</p></sec><sec id="s1-3"><title>NAb immunotherapy against SARS-CoV-1 and SARS-CoV-2</title><p>Will passive immunization with plasma from convalescent patients be beneficial for treating COVID-19? Anti-S antibodies seem to protect against lethal CoV challenge and clear the virus in mice and ferrets (<xref rid="bib26" ref-type="bibr">Du et al., 2008a</xref>; <xref rid="bib25" ref-type="bibr">Du et al., 2007</xref>; <xref rid="bib27" ref-type="bibr">Du et al., 2008b</xref>; <xref rid="bib31" ref-type="bibr">Fett et al., 2013</xref>). In a small experiment, SARS-CoV-2 infection reportedly protected against a second challenge of macaques, which was attributed to the development of protective antibodies (<xref rid="bib8" ref-type="bibr">Bao et al., 2020</xref>). The outcome of human clinical trials will, of course, outweigh animal-model experiments.</p><p>No significant adverse reactions were noted when plasma with high NAb titers were given to SARS-CoV-1 patients; benefits such as lower viral loads and earlier release from hospital were noted in retrospective analyses (<xref rid="bib17" ref-type="bibr">Cheng et al., 2005</xref>;&#x000a0;<xref rid="bib80" ref-type="bibr">Yeh et al., 2005</xref>;&#x000a0;<xref rid="bib62" ref-type="bibr">Soo et al., 2004</xref>; <xref rid="table1" ref-type="table">Table 1</xref>). Recently, five critically ill COVID-19 patients were transfused at 10&#x02013;22 days post-admission with a pool of plasma derived from five convalescent patients; the RBD-binding antibody endpoint titers in ELISA were&#x000a0;&#x0003e;1000, and the neutralization endpoint titers were&#x000a0;&#x0003e;40 (<xref rid="bib60" ref-type="bibr">Shen et al., 2020</xref>). All the patients (36&#x02013;65 years; three male, two female) were receiving mechanical ventilation. After plasma transfusion, body temperatures normalized, while organ-failure and respiratory-function scores improved to various extents. Nasopharyngeal viral loads decreased and became undetectable within 12 days in all five patients, while SARS-CoV-2 ELISA and NAb titers increased, reflecting the antibody-content of the transfused plasma. Thus, in this preliminary and necessarily uncontrolled case series of five critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS), the transfusion of NAb-containing convalescent plasma was associated with improved clinical status (<xref rid="bib60" ref-type="bibr">Shen et al., 2020</xref>). A subsequent larger study yielded similar results: ten patients with severe COVID-19 received 200 mL of convalescent plasma obtained from recently recovered donors with NAb inhibitory-dilution factors&#x000a0;&#x0003e;&#x000a0;640. Three days later, clinical, pulmonary-radiological, and laboratory parameters were improved, the latter including oxyhemoglobin saturation, lymphocyte counts, and C-reactive protein levels; viral loads in serum became undetectable in seven patients (<xref rid="bib29" ref-type="bibr">Duan et al., 2020</xref>;&#x000a0;see also additional smaller studies in <xref rid="table1" ref-type="table">Table 1</xref>). Overall, these studies showed plasma transfusion to be well tolerated. Although beneficial effects were reported, they could not be proven because the studies were not controlled and included other antiviral interventions.</p></sec><sec id="s1-4"><title>Can antibodies contribute to SARS pathogenesis?</title><p>Strategies for passive and active immunization to combat and prevent SARS-CoV-2 infection should take into account the pathogenesis of COVID-19, which can lead to death. The inflammatory response to SARS-CoV-2 is thought to drive or at least exacerbate the disease process, particularly during the second week after infection becomes symptomatic. How may these immune responses that modulate pathogenesis be affected by NAbs?</p><p>The lethal coronaviruses cause fatal acute lung injury (ALI) by driving hypercytokinemia and aggressive inflammation through incompletely understood mechanisms. In macaque models of SARS-CoV-1 infection and passive or active immunization, IgG specific for the S-protein was reported to exacerbate ALI by counteracting inflammation-resolving responses, abrogating wound-healing, promoting monocyte chemoattractant peptide-1 (MCP-1) and interleukin-8 (IL-8) production, and increasing proinflammatory monocyte and macrophage recruitment (<xref rid="bib49" ref-type="bibr">Liu et al., 2019</xref>). Likewise, in human patients who died of SARS-CoV-1 infection, pulmonary proinflammatory macrophages accumulated in the lungs, whereas wound-healing macrophages were absent (<xref rid="bib49" ref-type="bibr">Liu et al., 2019</xref>). Moreover, two observations noted above raise questions about the causal relationship between antibodies and severity of infection: NAb responses were faster in the patients who later died than in those who recovered (<xref rid="bib82" ref-type="bibr">Zhang et al., 2006</xref>; <xref rid="bib35" ref-type="bibr">Ho et al., 2005</xref>; <xref rid="bib49" ref-type="bibr">Liu et al., 2019</xref>), and older patients who had recovered from mild COVID-19, had significantly stronger NAb and S-protein-binding antibody responses than younger ones, whereas higher age is a major risk factor for lethal COVID-19 (<xref rid="bib79" ref-type="bibr">Wu et al., 2020</xref>).</p><p>In vitro, sera from subsequently deceased patients enhanced SARS-CoV-1 induced MCP-1 and IL-8 production by human monocyte&#x02013;derived wound-healing macrophages, whereas blockade of the Fc&#x003b3;R receptor reduced these effects (<xref rid="bib49" ref-type="bibr">Liu et al., 2019</xref>). One must be prudent when extrapolating from a macaque model of SARS-CoV-1 infection to human COVID-19 patients, but the antibody response to these lethal coronaviruses might play a role in disease progression, perhaps by formation of immune complexes, and by promoting macrophage infiltration and sustained inflammation. We hypothesize that there may be a causal link between seroconversion and the rapid deterioration that can take place in the second week after the first symptoms, but this remains to be established.</p><p>Other reports suggest that anti-S and other CoV-specific antibodies have pathogenic effects in animal models. Thus, multiple CoV vaccines were associated with an increase in eosinophilic proinflammatory pulmonary responses upon challenge of the immunized animals (<xref rid="bib10" ref-type="bibr">Bolles et al., 2011</xref>; <xref rid="bib37" ref-type="bibr">Honda-Okubo et al., 2015</xref>; <xref rid="bib40" ref-type="bibr">Iwata-Yoshikawa et al., 2014</xref>). Previous SARS-CoV-1 infection limited virus replication in African green monkeys but not lung inflammation, when the animals were re-challenged with the same virus (<xref rid="bib18" ref-type="bibr">Clay et al., 2012</xref>). It has not been determined which factors, such as viral dose and the extent of the innate and adaptive immune responses, yield these problematic effects. A particularly important knowledge gap is whether certain specificities and other properties of antibodies are responsible.</p><p>Pre-existing serum antibodies against influenza antigens were consistently associated with severe illness in patients during the 2009 influenza A H1N1 pandemic (<xref rid="bib66" ref-type="bibr">To et al., 2012</xref>; <xref rid="bib52" ref-type="bibr">Monsalvo et al., 2011</xref>). Of note is that those antibodies did not neutralize influenza virus (<xref rid="bib66" ref-type="bibr">To et al., 2012</xref>) and that immune complex formation was implicated as a pathogenic trigger (<xref rid="bib52" ref-type="bibr">Monsalvo et al., 2011</xref>). Whether these observations are linked to the findings reported by Liu et al. remains to be seen (<xref rid="bib49" ref-type="bibr">Liu et al., 2019</xref>).</p></sec><sec id="s1-5"><title>Antibody-dependent enhancement of infection (ADE)</title><p>Antibodies can also exacerbate viral infection by different mechanisms that have long been described (<xref rid="bib34" ref-type="bibr">Halstead, 1982</xref>). In the vaccine context, infection by alpha- and flaviviruses (such as Dengue and Zika viruses) is enhanced when the antibody occupancy on the virion-surface epitopes falls below a critical threshold (<xref rid="bib57" ref-type="bibr">Pierson and Diamond, 2015</xref>). This is the stoichiometric condition of an Fc-receptor-dependent form of ADE: the same antibodies that mediate ADE can neutralize and protect at higher occupancies on virions; alternatively, non-NAbs binding to epitopes exposed on the virion surface to antigens that are not functional for mediating entry may confer ADE (<xref rid="bib57" ref-type="bibr">Pierson and Diamond, 2015</xref>; <xref rid="bib46" ref-type="bibr">Klasse, 2014</xref>). The in vitro observations of ADE seem to account for the unfortunate outcome of recent Dengue vaccine trials with examples of worsened disease post-infection (<xref rid="bib39" ref-type="bibr">Hurtado&#x02010;Monz&#x000f3;n et al., 2020</xref>). ADE has been reported in the coronavirus literature, although most studies do not suggest that it will be as problematic as for alpha- and flaviviruses (<xref rid="bib41" ref-type="bibr">Jaume et al., 2011</xref>; <xref rid="bib44" ref-type="bibr">Kam et al., 2007</xref>; <xref rid="bib56" ref-type="bibr">Peeples, 2020</xref>; <xref rid="bib73" ref-type="bibr">Wan et al., 2020</xref>; <xref rid="bib74" ref-type="bibr">Wang et al., 2014</xref>; <xref rid="bib75" ref-type="bibr">Wang et al., 2016</xref>; <xref rid="bib24" ref-type="bibr">Diamond and Pierson, 2020</xref>; <xref rid="bib22" ref-type="bibr">de Alwis et al., 2020</xref>; <xref rid="bib14" ref-type="bibr">Burton and Walker, 2020</xref>). An exception is a study of vaccinia-vectored immunization of kittens with the S protein of the coronavirus feline infectious peritonitis virus. The vaccine induced NAbs poorly. After challenge with the infectious virus, deaths occurred sooner in the S-protein-vaccine group than in the vaccinia-only control group (<xref rid="bib24" ref-type="bibr">Diamond and Pierson, 2020</xref>; <xref rid="bib70" ref-type="bibr">Vennema et al., 1990</xref>).</p><p>Particular problems of ADE could arise in the face of an ongoing epidemic through NAbs at sub-protective levels, whether after incomplete vaccination courses or with poor and rapidly declining vaccine responses, as well as after passive immunization because of insufficient efficacy of NAbs in plasma or in purified polyclonal Ig and of MAbs.</p><p>One recent report described an unusual mechanism of MERS-CoV-infection enhancement in vitro, whereby the antibody binding to the S protein RBD promoted endocytic uptake by engaging with an Fc-receptor and triggered fusion by inducing a conformational change (<xref rid="bib41" ref-type="bibr">Jaume et al., 2011</xref>). It augurs well for vaccine development, however, that a SARS-CoV-2 RBD used as an immunogen elicited strong NAb responses in rats, without any ADE (<xref rid="bib59" ref-type="bibr">Quinlan et al., 2020</xref>). These topics will, no doubt, be investigated thoroughly as much-needed SARS-CoV-2 vaccines undergo pre-clinical and clinical testing.</p></sec><sec id="s1-6"><title>Possible improvements to immunotherapy</title><p>How could therapeutic interventions be improved so as to preserve the capacity of the infused NAbs to reduce virus replication while preventing the possible induction of fatal ALI through promotion of IL-8 and MCP-1 production and inflammatory macrophage accumulation? One precaution would be to administer NAbs with Fc deletions. In principle, this could be accomplished by enzymatic treatment of polyclonal IgGs purified from plasma to generate bivalent F(ab&#x02019;)two fragments. But in practice this would probably be too onerous. More feasible is the genetic engineering of neutralizing MAbs to eliminate the ability of the Fc-domains to bind activating FcR:s. Although such mutations would also eliminate potentially beneficial Fc-mediated effects such as ADCC, there is no evidence that these effector functions play a role in reducing viral load. For that goal, virus neutralization may be necessary and sufficient, at least during the COVID-19 acute phase.</p><p>An alternative neutralizing intervention, which eliminates some risks associated with polyclonal and monoclonal antibodies, is the use of a soluble, recombinant form of the ACE2 receptor, which is potent (nM range) and effective (depending on target cells) at blocking SARS-CoV-2 infection in vitro (<xref rid="bib47" ref-type="bibr">Lei et al., 2020</xref>). Since the SARS-CoV-2 S-protein has a 4&#x02013;20-fold higher affinity than the SARS-CoV-1 S-protein for ACE2, it may be more sensitive to this particular intervention, at least under some conditions of infection (<xref rid="bib78" ref-type="bibr">Wrapp et al., 2020</xref>; <xref rid="bib72" ref-type="bibr">Walls et al., 2020</xref>). Other advantages of these constructs are their potency and potential breadth of action against new viral variants. But if Fc-receptor ligation is pathogenic (<xref rid="bib49" ref-type="bibr">Liu et al., 2019</xref>), methods of increasing avidity other than fusing the soluble receptor to the Fc portion of IgG could be explored. The effects on angiotensin activation and its pharmacological inhibition may also need to be evaluated (<xref rid="bib36" ref-type="bibr">Hoffmann et al., 2020</xref>; <xref rid="bib7" ref-type="bibr">Aronson and Ferner, 2020</xref>).</p></sec><sec id="s1-7"><title>Conclusions</title><p>Plasma infusion as therapy for COVID-19 is a stop-gap measure that is now being used in a medical emergency. Within the next year, effective drugs are likely to emerge, and they may well include highly potent and specific MAbs to the SARS-CoV-2 S-protein. Animal experiments, particularly in macaques, will be valuable for comparing the capacity of different monoclonal and polyclonal antibodies, including combinations, or of recombinant receptor mimics, to clear SARS-CoV-2 infection. Ideally, the intervention should permit or even promote the emergence of favorable innate responses and the resolution of inflammation (<xref rid="bib54" ref-type="bibr">Nathan and Ding, 2010</xref>). Given the urgency of the COVID-19 pandemic, however, it may be impossible to perform such studies before human trials. Furthermore, differences in Fc-receptor biology may invalidate some extrapolations of antibody effects from macaques to humans (<xref rid="bib11" ref-type="bibr">Bournazos and Ravetch, 2017</xref>). In these circumstances, an awareness of what has occurred in other viral infections, particularly with SARS-CoV-1, as well as what is now being published on SARS-CoV-2, may guide both treatment strategies and the development of antibody-based vaccines (<xref rid="bib56" ref-type="bibr">Peeples, 2020</xref>; <xref rid="bib68" ref-type="bibr">Tseng et al., 2012</xref>; <xref rid="bib2" ref-type="bibr">Agrawal et al., 2016</xref>). Prospective or retrospective analyses of how the binding-antibody and NAb titers of transfused plasmas are associated with clinical improvements should also guide both MAb-based therapies and vaccine evaluation. If apparently antibody-mediated adverse events do occur, they too should help to improve these important public health measures against the COVID-19 pandemic.</p></sec></sec></body><back><sec sec-type="funding-information"><title>Funding Information</title><p>This paper was supported by the following grants:</p><list list-type="bullet"><list-item><p><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source>
<award-id>R01 AI36082</award-id> to John Moore.</p></list-item><list-item><p><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source>
<award-id>P01 AI110657</award-id> to John Moore.</p></list-item><list-item><p><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source>
<award-id>OPP1132237</award-id> to John Moore.</p></list-item><list-item><p><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source>
<award-id>INV-002022</award-id> to John Moore.</p></list-item></list></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by National Institutes of Health grants R01 AI36082 and P01 AI110657 and by Bill and Melinda Gates Foundation grants OPP1132237 and INV-002022. The Authors have no conflicts of interest to disclose.</p></ack><sec id="s2" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title><bold>Competing interests</bold></title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared.</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Accorsi</surname><given-names>P</given-names></name><name><surname>Berti</surname><given-names>P</given-names></name><name><surname>Angelis</surname><given-names>de</given-names></name></person-group><year>2020</year><article-title>Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19</article-title><source>Blood Transfusion = Trasfusione Del Sangue</source><volume>18</volume><fpage>163</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.transci.2020.102817</pub-id><pub-id pub-id-type="pmid">32453687</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>AS</given-names></name><name><surname>Tao</surname><given-names>X</given-names></name><name><surname>Algaissi</surname><given-names>A</given-names></name><name><surname>Garron</surname><given-names>T</given-names></name><name><surname>Narayanan</surname><given-names>K</given-names></name><name><surname>Peng</surname><given-names>BH</given-names></name><name><surname>Couch</surname><given-names>RB</given-names></name><name><surname>Tseng</surname><given-names>CT</given-names></name></person-group><year>2016</year><article-title>Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus</article-title><source>Human Vaccines &#x00026; Immunotherapeutics</source><volume>12</volume><fpage>2351</fpage><lpage>2356</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1177688</pub-id><?supplied-pmid 27269431?><pub-id pub-id-type="pmid">27269431</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>JY</given-names></name><name><surname>Sohn</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Cho</surname><given-names>Y</given-names></name><name><surname>Hyun</surname><given-names>JH</given-names></name><name><surname>Baek</surname><given-names>YJ</given-names></name><name><surname>Jeong</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Ku</surname><given-names>NS</given-names></name><name><surname>Yeom</surname><given-names>J-S</given-names></name><name><surname>Roh</surname><given-names>J</given-names></name><name><surname>Ahn</surname><given-names>MY</given-names></name><name><surname>Chin</surname><given-names>BS</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Yong</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>HO</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name></person-group><year>2020</year><article-title>Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea</article-title><source>Journal of Korean Medical Science</source><volume>35</volume><elocation-id>e149</elocation-id><pub-id pub-id-type="doi">10.3346/jkms.2020.35.e149</pub-id><pub-id pub-id-type="pmid">32281317</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akerstr&#x000f6;m</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>YJ</given-names></name><name><surname>Mirazimi</surname><given-names>A</given-names></name></person-group><year>2006</year><article-title>Amino acids 15-28 in the ectodomain of SARS coronavirus 3a protein induces neutralizing antibodies</article-title><source>FEBS Letters</source><volume>580</volume><fpage>3799</fpage><lpage>3803</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2006.06.002</pub-id><?supplied-pmid 16781713?><pub-id pub-id-type="pmid">16781713</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amanat</surname><given-names>F</given-names></name><name><surname>Stadlbauer</surname><given-names>D</given-names></name><name><surname>Strohmeier</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>THO</given-names></name><name><surname>Chromikova</surname><given-names>V</given-names></name><name><surname>McMahon</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Arunkumar</surname><given-names>GA</given-names></name><name><surname>Jurczyszak</surname><given-names>D</given-names></name><name><surname>Polanco</surname><given-names>J</given-names></name><name><surname>Bermudez-Gonzalez</surname><given-names>M</given-names></name><name><surname>Kleiner</surname><given-names>G</given-names></name><name><surname>Aydillo</surname><given-names>T</given-names></name><name><surname>Miorin</surname><given-names>L</given-names></name><name><surname>Fierer</surname><given-names>DS</given-names></name><name><surname>Lugo</surname><given-names>LA</given-names></name><name><surname>Kojic</surname><given-names>EM</given-names></name><name><surname>Stoever</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>STH</given-names></name><name><surname>Cunningham-Rundles</surname><given-names>C</given-names></name><name><surname>Felgner</surname><given-names>PL</given-names></name><name><surname>Moran</surname><given-names>T</given-names></name><name><surname>Garc&#x000ed;a-Sastre</surname><given-names>A</given-names></name><name><surname>Caplivski</surname><given-names>D</given-names></name><name><surname>Cheng</surname><given-names>AC</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name><name><surname>Vapalahti</surname><given-names>O</given-names></name><name><surname>Hepojoki</surname><given-names>JM</given-names></name><name><surname>Simon</surname><given-names>V</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name></person-group><year>2020</year><article-title>A serological assay to detect SARS-CoV-2 seroconversion in humans</article-title><source>Nature Medicine</source><volume>5</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1038/s41591-020-0913-5</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amanat</surname><given-names>F</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name></person-group><year>2020</year><article-title>SARS-CoV-2 vaccines: status report</article-title><source>Immunity</source><volume>52</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.03.007</pub-id><pub-id pub-id-type="pmid">32259480</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aronson</surname><given-names>JK</given-names></name><name><surname>Ferner</surname><given-names>RE</given-names></name></person-group><year>2020</year><article-title>Drugs and the renin-angiotensin system in covid-19</article-title><source>BMJ</source><volume>369</volume><elocation-id>m1313</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.m1313</pub-id><?supplied-pmid 32241880?><pub-id pub-id-type="pmid">32241880</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Wei Deng</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name><name><surname>Lv</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>F</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Gong</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name></person-group><year>2020</year><article-title>Reinfection could not occur in SARS-CoV-2 infected rhesus macaques</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.03.13.990226</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloch</surname><given-names>EM</given-names></name><name><surname>Shoham</surname><given-names>S</given-names></name><name><surname>Casadevall</surname><given-names>A</given-names></name></person-group><year>2020</year><article-title>Deployment of convalescent plasma for the prevention and treatment of COVID-19</article-title><source>The Journal of Clinical Investigation</source><volume>18</volume><elocation-id>138745</elocation-id><pub-id pub-id-type="doi">10.1172/JCI138745</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolles</surname><given-names>M</given-names></name><name><surname>Deming</surname><given-names>D</given-names></name><name><surname>Long</surname><given-names>K</given-names></name><name><surname>Agnihothram</surname><given-names>S</given-names></name><name><surname>Whitmore</surname><given-names>A</given-names></name><name><surname>Ferris</surname><given-names>M</given-names></name><name><surname>Funkhouser</surname><given-names>W</given-names></name><name><surname>Gralinski</surname><given-names>L</given-names></name><name><surname>Totura</surname><given-names>A</given-names></name><name><surname>Heise</surname><given-names>M</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><year>2011</year><article-title>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</article-title><source>Journal of Virology</source><volume>85</volume><fpage>12201</fpage><lpage>12215</lpage><pub-id pub-id-type="doi">10.1128/JVI.06048-11</pub-id><?supplied-pmid 21937658?><pub-id pub-id-type="pmid">21937658</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bournazos</surname><given-names>S</given-names></name><name><surname>Ravetch</surname><given-names>JV</given-names></name></person-group><year>2017</year><article-title>Anti-retroviral antibody Fc&#x003b3;R-mediated effector functions</article-title><source>Immunological Reviews</source><volume>275</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1111/imr.12482</pub-id><?supplied-pmid 28133801?><pub-id pub-id-type="pmid">28133801</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JF</given-names></name><name><surname>Dye</surname><given-names>JM</given-names></name><name><surname>Tozay</surname><given-names>S</given-names></name><name><surname>Jeh-Mulbah</surname><given-names>G</given-names></name><name><surname>Wohl</surname><given-names>DA</given-names></name><name><surname>Fischer</surname><given-names>WA</given-names></name><name><surname>Cunningham</surname><given-names>CK</given-names></name><name><surname>Rowe</surname><given-names>K</given-names></name><name><surname>Zacharias</surname><given-names>P</given-names></name><name><surname>van Hasselt</surname><given-names>J</given-names></name><name><surname>Norwood</surname><given-names>DA</given-names></name><name><surname>Thielman</surname><given-names>NM</given-names></name><name><surname>Zak</surname><given-names>SE</given-names></name><name><surname>Hoover</surname><given-names>DL</given-names></name></person-group><year>2018</year><article-title>Anti-Ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with ebola virus disease</article-title><source>The Journal of Infectious Diseases</source><volume>218</volume><fpage>555</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy199</pub-id><?supplied-pmid 29659889?><pub-id pub-id-type="pmid">29659889</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchholz</surname><given-names>UJ</given-names></name><name><surname>Bukreyev</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Lamirande</surname><given-names>EW</given-names></name><name><surname>Murphy</surname><given-names>BR</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Collins</surname><given-names>PL</given-names></name></person-group><year>2004</year><article-title>Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity</article-title><source>PNAS</source><volume>101</volume><fpage>9804</fpage><lpage>9809</lpage><pub-id pub-id-type="doi">10.1073/pnas.0403492101</pub-id><?supplied-pmid 15210961?><pub-id pub-id-type="pmid">15210961</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Walker</surname><given-names>LM</given-names></name></person-group><year>2020</year><article-title>Rational vaccine design in the time of COVID-19</article-title><source>Cell Host &#x00026; Microbe</source><volume>27</volume><fpage>695</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.04.022</pub-id><?supplied-pmid 32407707?><pub-id pub-id-type="pmid">32407707</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year>2019</year><article-title>Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic</article-title><source>Nature Medicine</source><volume>25</volume><fpage>547</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0412-8</pub-id><?supplied-pmid 30936546?><pub-id pub-id-type="pmid">30936546</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Ba</surname><given-names>L</given-names></name><name><surname>Yi</surname><given-names>CE</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Tu</surname><given-names>X</given-names></name><name><surname>Gettie</surname><given-names>A</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name></person-group><year>2005</year><article-title>Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region</article-title><source>Journal of Virology</source><volume>79</volume><fpage>2678</fpage><lpage>2688</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.5.2678-2688.2005</pub-id><?supplied-pmid 15708987?><pub-id pub-id-type="pmid">15708987</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Soo</surname><given-names>YO</given-names></name><name><surname>Wong</surname><given-names>WS</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Wong</surname><given-names>KC</given-names></name><name><surname>Leung</surname><given-names>CB</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name></person-group><year>2005</year><article-title>Use of convalescent plasma therapy in SARS patients in Hong Kong</article-title><source>European Journal of Clinical Microbiology &#x00026; Infectious Diseases</source><volume>24</volume><fpage>44</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1007/s10096-004-1271-9</pub-id><?supplied-pmid 15616839?><pub-id pub-id-type="pmid">15616839</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clay</surname><given-names>C</given-names></name><name><surname>Donart</surname><given-names>N</given-names></name><name><surname>Fomukong</surname><given-names>N</given-names></name><name><surname>Knight</surname><given-names>JB</given-names></name><name><surname>Lei</surname><given-names>W</given-names></name><name><surname>Price</surname><given-names>L</given-names></name><name><surname>Hahn</surname><given-names>F</given-names></name><name><surname>Van Westrienen</surname><given-names>J</given-names></name><name><surname>Harrod</surname><given-names>KS</given-names></name></person-group><year>2012</year><article-title>Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge</article-title><source>Journal of Virology</source><volume>86</volume><fpage>4234</fpage><lpage>4244</lpage><pub-id pub-id-type="doi">10.1128/JVI.06791-11</pub-id><?supplied-pmid 22345460?><pub-id pub-id-type="pmid">22345460</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Passini</surname><given-names>N</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name></person-group><year>2016</year><article-title>Rapid generation of a human monoclonal antibody to combat middle east respiratory syndrome</article-title><source>Journal of Infection and Public Health</source><volume>9</volume><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2016.04.003</pub-id><?supplied-pmid 27102927?><pub-id pub-id-type="pmid">27102927</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Cameroni</surname><given-names>E</given-names></name><name><surname>Guarino</surname><given-names>B</given-names></name><name><surname>Kallewaard</surname><given-names>NL</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year>2017</year><article-title>Tackling influenza with broadly neutralizing antibodies</article-title><source>Current Opinion in Virology</source><volume>24</volume><fpage>60</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2017.03.002</pub-id><?supplied-pmid 28527859?><pub-id pub-id-type="pmid">28527859</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coughlin</surname><given-names>M</given-names></name><name><surname>Lou</surname><given-names>G</given-names></name><name><surname>Martinez</surname><given-names>O</given-names></name><name><surname>Masterman</surname><given-names>SK</given-names></name><name><surname>Olsen</surname><given-names>OA</given-names></name><name><surname>Moksa</surname><given-names>AA</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Babcook</surname><given-names>JS</given-names></name><name><surname>Prabhakar</surname><given-names>BS</given-names></name></person-group><year>2007</year><article-title>Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse</article-title><source>Virology</source><volume>361</volume><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.09.029</pub-id><?supplied-pmid 17161858?><pub-id pub-id-type="pmid">17161858</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Alwis</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Gan</surname><given-names>ES</given-names></name><name><surname>Ooi</surname><given-names>EE</given-names></name></person-group><year>2020</year><article-title>Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development</article-title><source>EBioMedicine</source><volume>55</volume><elocation-id>102768</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102768</pub-id><?supplied-pmid 32344202?><pub-id pub-id-type="pmid">32344202</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhama</surname><given-names>K</given-names></name><name><surname>Sharun</surname><given-names>K</given-names></name><name><surname>Tiwari</surname><given-names>R</given-names></name><name><surname>Dadar</surname><given-names>M</given-names></name><name><surname>Malik</surname><given-names>YS</given-names></name><name><surname>Singh</surname><given-names>KP</given-names></name><name><surname>Chaicumpa</surname><given-names>W</given-names></name></person-group><year>2020</year><article-title>COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics</article-title><source>Human Vaccines &#x00026; Immunotherapeutics</source><volume>57</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1735227</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Pierson</surname><given-names>TC</given-names></name></person-group><year>2020</year><article-title>The challenges of vaccine development against a new virus during a pandemic</article-title><source>Cell Host &#x00026; Microbe</source><volume>27</volume><fpage>699</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.04.021</pub-id><?supplied-pmid 32407708?><pub-id pub-id-type="pmid">32407708</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>BJ</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><year>2007</year><article-title>Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model</article-title><source>Vaccine</source><volume>25</volume><fpage>2832</fpage><lpage>2838</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.10.031</pub-id><?supplied-pmid 17092615?><pub-id pub-id-type="pmid">17092615</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Sui</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><name><surname>Jin</surname><given-names>DY</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>BJ</given-names></name></person-group><year>2008a</year><article-title>Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection</article-title><source>The Journal of Immunology</source><volume>180</volume><fpage>948</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.2.948</pub-id><?supplied-pmid 18178835?><pub-id pub-id-type="pmid">18178835</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>DY</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>BJ</given-names></name></person-group><year>2008b</year><article-title>Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection</article-title><source>Vaccine</source><volume>26</volume><fpage>1644</fpage><lpage>1651</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.01.025</pub-id><?supplied-pmid 18289745?><pub-id pub-id-type="pmid">18289745</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Jin</surname><given-names>G</given-names></name></person-group><year>2005</year><article-title>A human SARS-CoV neutralizing antibody against epitope on S2 protein</article-title><source>Biochemical and Biophysical Research Communications</source><volume>333</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.05.089</pub-id><pub-id pub-id-type="pmid">15939399</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>K</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><year>2020</year><article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title><source>PNAS</source><volume>117</volume><fpage>9490</fpage><lpage>9496</lpage><pub-id pub-id-type="doi">10.1073/pnas.2004168117</pub-id><?supplied-pmid 32253318?><pub-id pub-id-type="pmid">32253318</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elshabrawy</surname><given-names>HA</given-names></name><name><surname>Coughlin</surname><given-names>MM</given-names></name><name><surname>Baker</surname><given-names>SC</given-names></name><name><surname>Prabhakar</surname><given-names>BS</given-names></name></person-group><year>2012</year><article-title>Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e50366</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0050366</pub-id><?supplied-pmid 23185609?><pub-id pub-id-type="pmid">23185609</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fett</surname><given-names>C</given-names></name><name><surname>DeDiego</surname><given-names>ML</given-names></name><name><surname>Regla-Nava</surname><given-names>JA</given-names></name><name><surname>Enjuanes</surname><given-names>L</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><year>2013</year><article-title>Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein</article-title><source>Journal of Virology</source><volume>87</volume><fpage>6551</fpage><lpage>6559</lpage><pub-id pub-id-type="doi">10.1128/JVI.00087-13</pub-id><?supplied-pmid 23576515?><pub-id pub-id-type="pmid">23576515</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>BS</given-names></name></person-group><year>2020</year><article-title>Rapid COVID-19 vaccine development</article-title><source>Science</source><volume>368</volume><fpage>945</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1126/science.abb8923</pub-id><?supplied-pmid 32385100?><pub-id pub-id-type="pmid">32385100</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenough</surname><given-names>TC</given-names></name><name><surname>Babcock</surname><given-names>GJ</given-names></name><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Hernandez</surname><given-names>HJ</given-names></name><name><surname>Thomas</surname><given-names>WD</given-names></name><name><surname>Coccia</surname><given-names>JA</given-names></name><name><surname>Graziano</surname><given-names>RF</given-names></name><name><surname>Srinivasan</surname><given-names>M</given-names></name><name><surname>Lowy</surname><given-names>I</given-names></name><name><surname>Finberg</surname><given-names>RW</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Vogel</surname><given-names>L</given-names></name><name><surname>Somasundaran</surname><given-names>M</given-names></name><name><surname>Luzuriaga</surname><given-names>K</given-names></name><name><surname>Sullivan</surname><given-names>JL</given-names></name><name><surname>Ambrosino</surname><given-names>DM</given-names></name></person-group><year>2005</year><article-title>Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice</article-title><source>The Journal of Infectious Diseases</source><volume>191</volume><fpage>507</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1086/427242</pub-id><?supplied-pmid 15655773?><pub-id pub-id-type="pmid">15655773</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name></person-group><year>1982</year><article-title>Immune enhancement of viral infection</article-title><source>Progress in Allergy</source><volume>31</volume><fpage>301</fpage><lpage>364</lpage><?supplied-pmid 6292921?><pub-id pub-id-type="pmid">6292921</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>MS</given-names></name><name><surname>Chen</surname><given-names>WJ</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Lin</surname><given-names>SF</given-names></name><name><surname>Wang</surname><given-names>MC</given-names></name><name><surname>Di</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>YT</given-names></name><name><surname>Liu</surname><given-names>CL</given-names></name><name><surname>Chang</surname><given-names>SC</given-names></name><name><surname>Chao</surname><given-names>CL</given-names></name><name><surname>King</surname><given-names>CC</given-names></name><name><surname>Chiou</surname><given-names>JM</given-names></name><name><surname>Su</surname><given-names>IJ</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name></person-group><year>2005</year><article-title>Neutralizing antibody response and SARS severity</article-title><source>Emerging Infectious Diseases</source><volume>11</volume><fpage>1730</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.3201/eid1111.040659</pub-id><?supplied-pmid 16318725?><pub-id pub-id-type="pmid">16318725</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><name><surname>Schiergens</surname><given-names>TS</given-names></name><name><surname>Herrler</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>NH</given-names></name><name><surname>Nitsche</surname><given-names>A</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S</given-names></name></person-group><year>2020</year><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><volume>181</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><?supplied-pmid 32142651?><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda-Okubo</surname><given-names>Y</given-names></name><name><surname>Barnard</surname><given-names>D</given-names></name><name><surname>Ong</surname><given-names>CH</given-names></name><name><surname>Peng</surname><given-names>BH</given-names></name><name><surname>Tseng</surname><given-names>CT</given-names></name><name><surname>Petrovsky</surname><given-names>N</given-names></name></person-group><year>2015</year><article-title>Severe acute respiratory syndrome-associated coronavirus vaccines formulated with Delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology</article-title><source>Journal of Virology</source><volume>89</volume><fpage>2995</fpage><lpage>3007</lpage><pub-id pub-id-type="doi">10.1128/JVI.02980-14</pub-id><?supplied-pmid 25520500?><pub-id pub-id-type="pmid">25520500</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>To</surname><given-names>KK</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Chan</surname><given-names>K</given-names></name><name><surname>Yan</surname><given-names>WW</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Watt</surname><given-names>CL</given-names></name><name><surname>Chan</surname><given-names>WM</given-names></name><name><surname>Lai</surname><given-names>KY</given-names></name><name><surname>Koo</surname><given-names>CK</given-names></name><name><surname>Buckley</surname><given-names>T</given-names></name><name><surname>Chow</surname><given-names>FL</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name><name><surname>Chan</surname><given-names>HS</given-names></name><name><surname>Ching</surname><given-names>CK</given-names></name><name><surname>Tang</surname><given-names>BS</given-names></name><name><surname>Lau</surname><given-names>CC</given-names></name><name><surname>Li</surname><given-names>IW</given-names></name><name><surname>Liu</surname><given-names>SH</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Lin</surname><given-names>CK</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><year>2011</year><article-title>Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection</article-title><source>Clinical Infectious Diseases</source><volume>52</volume><fpage>447</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1093/cid/ciq106</pub-id><?supplied-pmid 21248066?><pub-id pub-id-type="pmid">21248066</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurtado&#x02010;Monz&#x000f3;n</surname><given-names>AM</given-names></name><name><surname>Cordero&#x02010;Rivera</surname><given-names>CD</given-names></name><name><surname>Farfan&#x02010;Morales</surname><given-names>CN</given-names></name><name><surname>Osuna&#x02010;Ramos</surname><given-names>JF</given-names></name><name><surname>De Jes&#x000fa;s&#x02010;Gonz&#x000e1;lez</surname><given-names>LA</given-names></name><name><surname>Reyes&#x02010;Ruiz</surname><given-names>JM</given-names></name><name><surname>&#x000c1;ngel</surname><given-names>RM</given-names></name></person-group><year>2020</year><article-title>The role of anti&#x02010;flavivirus humoral immune response in protection and pathogenesis</article-title><source>Reviews in Medical Virology</source><volume>65</volume><elocation-id>e2100</elocation-id><pub-id pub-id-type="doi">10.1002/rmv.2100</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name><name><surname>Uda</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Tsunetsugu-Yokota</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Morikawa</surname><given-names>S</given-names></name><name><surname>Tashiro</surname><given-names>M</given-names></name><name><surname>Sata</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Nagata</surname><given-names>N</given-names></name></person-group><year>2014</year><article-title>Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine</article-title><source>Journal of Virology</source><volume>88</volume><fpage>8597</fpage><lpage>8614</lpage><pub-id pub-id-type="doi">10.1128/JVI.00983-14</pub-id><?supplied-pmid 24850731?><pub-id pub-id-type="pmid">24850731</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaume</surname><given-names>M</given-names></name><name><surname>Yip</surname><given-names>MS</given-names></name><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Leung</surname><given-names>HL</given-names></name><name><surname>Li</surname><given-names>PH</given-names></name><name><surname>Kien</surname><given-names>F</given-names></name><name><surname>Dutry</surname><given-names>I</given-names></name><name><surname>Callendret</surname><given-names>B</given-names></name><name><surname>Escriou</surname><given-names>N</given-names></name><name><surname>Altmeyer</surname><given-names>R</given-names></name><name><surname>Nal</surname><given-names>B</given-names></name><name><surname>Da&#x000eb;ron</surname><given-names>M</given-names></name><name><surname>Bruzzone</surname><given-names>R</given-names></name><name><surname>Peiris</surname><given-names>JS</given-names></name></person-group><year>2011</year><article-title>Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent fc&#x003b3;r pathway</article-title><source>Journal of Virology</source><volume>85</volume><fpage>10582</fpage><lpage>10597</lpage><pub-id pub-id-type="doi">10.1128/JVI.00671-11</pub-id><?supplied-pmid 21775467?><pub-id pub-id-type="pmid">21775467</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jawhara</surname><given-names>S</given-names></name></person-group><year>2020</year><article-title>Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients?</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>2272</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21072272</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Shan</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Lan</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><year>2020</year><article-title>Human neutralizing antibodies elicited by SARS-CoV-2 infection</article-title><source>Nature</source><pub-id pub-id-type="doi">10.1038/s41586-020-2380-z</pub-id><?supplied-pmid 32454513?><pub-id pub-id-type="pmid">32454513</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>YW</given-names></name><name><surname>Kien</surname><given-names>F</given-names></name><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Cheung</surname><given-names>YC</given-names></name><name><surname>Lamirande</surname><given-names>EW</given-names></name><name><surname>Vogel</surname><given-names>L</given-names></name><name><surname>Chu</surname><given-names>SL</given-names></name><name><surname>Tse</surname><given-names>J</given-names></name><name><surname>Guarner</surname><given-names>J</given-names></name><name><surname>Zaki</surname><given-names>SR</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Peiris</surname><given-names>M</given-names></name><name><surname>Nal</surname><given-names>B</given-names></name><name><surname>Altmeyer</surname><given-names>R</given-names></name></person-group><year>2007</year><article-title>Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro</article-title><source>Vaccine</source><volume>25</volume><fpage>729</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.08.011</pub-id><?supplied-pmid 17049691?><pub-id pub-id-type="pmid">17049691</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klasse</surname><given-names>PJ</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name><name><surname>Cerutti</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name></person-group><year>2012</year><article-title>How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?</article-title><source>AIDS Research and Human Retroviruses</source><volume>28</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1089/aid.2011.0053</pub-id><?supplied-pmid 21495876?><pub-id pub-id-type="pmid">21495876</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klasse</surname><given-names>PJ</given-names></name></person-group><year>2014</year><article-title>Neutralization of virus infectivity by antibodies: old problems in new perspectives</article-title><source>Advances in Biology</source><volume>2014</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1155/2014/157895</pub-id><?supplied-pmid 27099867?><pub-id pub-id-type="pmid">27099867</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>C</given-names></name><name><surname>Qian</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Ding</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name></person-group><year>2020</year><article-title>Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2070</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16048-4</pub-id><?supplied-pmid 32332765?><pub-id pub-id-type="pmid">32332765</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>DT</given-names></name><name><surname>Tam</surname><given-names>FC</given-names></name><name><surname>Ma</surname><given-names>CH</given-names></name><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Cheung</surname><given-names>JL</given-names></name><name><surname>Niu</surname><given-names>H</given-names></name><name><surname>Tam</surname><given-names>JS</given-names></name><name><surname>Lim</surname><given-names>PL</given-names></name></person-group><year>2004</year><article-title>Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid</article-title><source>The Journal of Infectious Diseases</source><volume>190</volume><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1086/422040</pub-id><?supplied-pmid 15216476?><pub-id pub-id-type="pmid">15216476</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Kwok</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Nishiura</surname><given-names>K</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Cheung</surname><given-names>K-W</given-names></name><name><surname>Chan</surname><given-names>K-H</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Lackner</surname><given-names>A</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name><name><surname>Yuen</surname><given-names>K-Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><year>2019</year><article-title>Anti&#x02013;spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection</article-title><source>JCI Insight</source><volume>4</volume><elocation-id>123158</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.123158</pub-id><pub-id pub-id-type="pmid">30830861</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luke</surname><given-names>TC</given-names></name><name><surname>Kilbane</surname><given-names>EM</given-names></name><name><surname>Jackson</surname><given-names>JL</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name></person-group><year>2006</year><article-title>Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?</article-title><source>Annals of Internal Medicine</source><volume>145</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-145-8-200610170-00139</pub-id><?supplied-pmid 16940336?><pub-id pub-id-type="pmid">16940336</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mair-Jenkins</surname><given-names>J</given-names></name><name><surname>Saavedra-Campos</surname><given-names>M</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Cleary</surname><given-names>P</given-names></name><name><surname>Khaw</surname><given-names>FM</given-names></name><name><surname>Lim</surname><given-names>WS</given-names></name><name><surname>Makki</surname><given-names>S</given-names></name><name><surname>Rooney</surname><given-names>KD</given-names></name><name><surname>Nguyen-Van-Tam</surname><given-names>JS</given-names></name><name><surname>Beck</surname><given-names>CR</given-names></name><collab>Convalescent Plasma Study Group</collab></person-group><year>2015</year><article-title>The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis</article-title><source>Journal of Infectious Diseases</source><volume>211</volume><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu396</pub-id><?supplied-pmid 25030060?><pub-id pub-id-type="pmid">25030060</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monsalvo</surname><given-names>AC</given-names></name><name><surname>Batalle</surname><given-names>JP</given-names></name><name><surname>Lopez</surname><given-names>MF</given-names></name><name><surname>Krause</surname><given-names>JC</given-names></name><name><surname>Klemenc</surname><given-names>J</given-names></name><name><surname>Hernandez</surname><given-names>JZ</given-names></name><name><surname>Maskin</surname><given-names>B</given-names></name><name><surname>Bugna</surname><given-names>J</given-names></name><name><surname>Rubinstein</surname><given-names>C</given-names></name><name><surname>Aguilar</surname><given-names>L</given-names></name><name><surname>Dalurzo</surname><given-names>L</given-names></name><name><surname>Libster</surname><given-names>R</given-names></name><name><surname>Savy</surname><given-names>V</given-names></name><name><surname>Baumeister</surname><given-names>E</given-names></name><name><surname>Aguilar</surname><given-names>L</given-names></name><name><surname>Cabral</surname><given-names>G</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><name><surname>Solari</surname><given-names>L</given-names></name><name><surname>Weller</surname><given-names>KP</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Echavarria</surname><given-names>M</given-names></name><name><surname>Edwards</surname><given-names>KM</given-names></name><name><surname>Chappell</surname><given-names>JD</given-names></name><name><surname>Crowe</surname><given-names>JE</given-names></name><name><surname>Williams</surname><given-names>JV</given-names></name><name><surname>Melendi</surname><given-names>GA</given-names></name><name><surname>Polack</surname><given-names>FP</given-names></name></person-group><year>2011</year><article-title>Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes</article-title><source>Nature Medicine</source><volume>17</volume><fpage>195</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1038/nm.2262</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mupapa</surname><given-names>K</given-names></name><name><surname>Massamba</surname><given-names>M</given-names></name><name><surname>Kibadi</surname><given-names>K</given-names></name><name><surname>Kuvula</surname><given-names>K</given-names></name><name><surname>Bwaka</surname><given-names>A</given-names></name><name><surname>Kipasa</surname><given-names>M</given-names></name><name><surname>Colebunders</surname><given-names>R</given-names></name><name><surname>Muyembe-Tamfum</surname><given-names>JJ</given-names></name></person-group><year>1999</year><article-title>Treatment of ebola hemorrhagic fever with blood transfusions from convalescent patients&#x000a0;international scientific and technical committee</article-title><source>The Journal of Infectious Diseases</source><volume>179</volume><fpage>S18</fpage><lpage>S23</lpage><pub-id pub-id-type="doi">10.1086/514298</pub-id><?supplied-pmid 9988160?><pub-id pub-id-type="pmid">9988160</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>C</given-names></name><name><surname>Ding</surname><given-names>A</given-names></name></person-group><year>2010</year><article-title>Nonresolving inflammation</article-title><source>Cell</source><volume>140</volume><fpage>871</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.02.029</pub-id><?supplied-pmid 20303877?><pub-id pub-id-type="pmid">20303877</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Mi</surname><given-names>D</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Mu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>Z</given-names></name></person-group><year>2020</year><article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1620</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15562-9</pub-id><?supplied-pmid 32221306?><pub-id pub-id-type="pmid">32221306</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peeples</surname><given-names>L</given-names></name></person-group><year>2020</year><article-title>News feature: avoiding pitfalls in the pursuit of a COVID-19 vaccine</article-title><source>PNAS</source><volume>117</volume><fpage>8218</fpage><lpage>8221</lpage><pub-id pub-id-type="doi">10.1073/pnas.2005456117</pub-id><?supplied-pmid 32229574?><pub-id pub-id-type="pmid">32229574</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierson</surname><given-names>TC</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group><year>2015</year><article-title>A game of numbers: the stoichiometry of antibody-mediated neutralization of Flavivirus infection</article-title><source>Progress in Molecular Biology and Translational Science</source><volume>129</volume><fpage>141</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/bs.pmbts.2014.10.005</pub-id><?supplied-pmid 25595803?><pub-id pub-id-type="pmid">25595803</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Beltramello</surname><given-names>M</given-names></name><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Bianchi</surname><given-names>S</given-names></name><name><surname>Jaconi</surname><given-names>S</given-names></name><name><surname>Culap</surname><given-names>K</given-names></name><name><surname>Zatta</surname><given-names>F</given-names></name><name><surname>De Marco</surname><given-names>A</given-names></name><name><surname>Peter</surname><given-names>A</given-names></name><name><surname>Guarino</surname><given-names>B</given-names></name><name><surname>Spreafico</surname><given-names>R</given-names></name><name><surname>Cameroni</surname><given-names>E</given-names></name><name><surname>Case</surname><given-names>JB</given-names></name><name><surname>Chen</surname><given-names>RE</given-names></name><name><surname>Havenar-Daughton</surname><given-names>C</given-names></name><name><surname>Snell</surname><given-names>G</given-names></name><name><surname>Telenti</surname><given-names>A</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Fink</surname><given-names>K</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name></person-group><year>2020</year><article-title>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody</article-title><source>Nature</source><pub-id pub-id-type="doi">10.1038/s41586-020-2349-y</pub-id><?supplied-pmid 32422645?><pub-id pub-id-type="pmid">32422645</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>BD</given-names></name><name><surname>Mou</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Ojha</surname><given-names>A</given-names></name><name><surname>Parcells</surname><given-names>MS</given-names></name><name><surname>Luo</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name></person-group><year>2020</year><article-title>The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.04.10.036418.</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Qing</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><year>2020</year><article-title>Treatment of 5 critically ill patients with COVID-19 with convalescent plasma</article-title><source>JAMA</source><volume>323</volume><elocation-id>1582</elocation-id><pub-id pub-id-type="doi">10.1001/jama.2020.4783</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegrist</surname><given-names>CA</given-names></name><name><surname>Aspinall</surname><given-names>R</given-names></name></person-group><year>2009</year><article-title>B-cell responses to vaccination at the extremes of age</article-title><source>Nature Reviews Immunology</source><volume>9</volume><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/nri2508</pub-id><?supplied-pmid 19240757?><pub-id pub-id-type="pmid">19240757</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soo</surname><given-names>YO</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Tsang</surname><given-names>KK</given-names></name><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Sung</surname><given-names>JJ</given-names></name></person-group><year>2004</year><article-title>Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients</article-title><source>Clinical Microbiology and Infection</source><volume>10</volume><fpage>676</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2004.00956.x</pub-id><?supplied-pmid 15214887?><pub-id pub-id-type="pmid">15214887</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>Tamin</surname><given-names>A</given-names></name><name><surname>Matthews</surname><given-names>LJ</given-names></name><name><surname>Wong</surname><given-names>SK</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Tallarico</surname><given-names>AS</given-names></name><name><surname>Olurinde</surname><given-names>M</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name><name><surname>Anderson</surname><given-names>LJ</given-names></name><name><surname>Bellini</surname><given-names>WJ</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Marasco</surname><given-names>WA</given-names></name></person-group><year>2004</year><article-title>Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association</article-title><source>PNAS</source><volume>101</volume><fpage>2536</fpage><lpage>2541</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307140101</pub-id><?supplied-pmid 14983044?><pub-id pub-id-type="pmid">14983044</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>HC</given-names></name><name><surname>Roback</surname><given-names>JD</given-names></name></person-group><year>2020</year><article-title>Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic</article-title><source>Transfusion Medicine Reviews</source><volume>S0887-7963</volume><elocation-id>30025</elocation-id><pub-id pub-id-type="doi">10.1016/j.tmrv.2020.04.001</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ter Meulen</surname><given-names>J</given-names></name><name><surname>van den Brink</surname><given-names>EN</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Marissen</surname><given-names>WE</given-names></name><name><surname>Leung</surname><given-names>CS</given-names></name><name><surname>Cox</surname><given-names>F</given-names></name><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Bakker</surname><given-names>AQ</given-names></name><name><surname>Bogaards</surname><given-names>JA</given-names></name><name><surname>van Deventer</surname><given-names>E</given-names></name><name><surname>Preiser</surname><given-names>W</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name><name><surname>Chow</surname><given-names>VT</given-names></name><name><surname>de Kruif</surname><given-names>J</given-names></name><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name></person-group><year>2006</year><article-title>Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants</article-title><source>PLOS Medicine</source><volume>3</volume><elocation-id>e237</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0030237</pub-id><?supplied-pmid 16796401?><pub-id pub-id-type="pmid">16796401</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>To</surname><given-names>KK</given-names></name><name><surname>Zhang</surname><given-names>AJ</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Ip</surname><given-names>WC</given-names></name><name><surname>Wong</surname><given-names>RT</given-names></name><name><surname>Ng</surname><given-names>JC</given-names></name><name><surname>Chan</surname><given-names>JF</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><year>2012</year><article-title>High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza</article-title><source>Clinical and Vaccine Immunology : CVI</source><volume>19</volume><fpage>1012</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1128/CVI.00081-12</pub-id><?supplied-pmid 22573737?><pub-id pub-id-type="pmid">22573737</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>To</surname><given-names>KK</given-names></name><name><surname>Tsang</surname><given-names>OT</given-names></name><name><surname>Leung</surname><given-names>WS</given-names></name><name><surname>Tam</surname><given-names>AR</given-names></name><name><surname>Wu</surname><given-names>TC</given-names></name><name><surname>Lung</surname><given-names>DC</given-names></name><name><surname>Yip</surname><given-names>CC</given-names></name><name><surname>Cai</surname><given-names>JP</given-names></name><name><surname>Chan</surname><given-names>JM</given-names></name><name><surname>Chik</surname><given-names>TS</given-names></name><name><surname>Lau</surname><given-names>DP</given-names></name><name><surname>Choi</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name><name><surname>Chan</surname><given-names>WM</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Ip</surname><given-names>JD</given-names></name><name><surname>Ng</surname><given-names>AC</given-names></name><name><surname>Poon</surname><given-names>RW</given-names></name><name><surname>Luo</surname><given-names>CT</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Chan</surname><given-names>JF</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><year>2020</year><article-title>Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study</article-title><source>The Lancet. Infectious Diseases</source><volume>20</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30196-1</pub-id><?supplied-pmid 32213337?><pub-id pub-id-type="pmid">32213337</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>CT</given-names></name><name><surname>Sbrana</surname><given-names>E</given-names></name><name><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name><name><surname>Newman</surname><given-names>PC</given-names></name><name><surname>Garron</surname><given-names>T</given-names></name><name><surname>Atmar</surname><given-names>RL</given-names></name><name><surname>Peters</surname><given-names>CJ</given-names></name><name><surname>Couch</surname><given-names>RB</given-names></name></person-group><year>2012</year><article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e35421</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035421</pub-id><?supplied-pmid 22536382?><pub-id pub-id-type="pmid">22536382</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Brink</surname><given-names>EN</given-names></name><name><surname>Ter Meulen</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>F</given-names></name><name><surname>Jongeneelen</surname><given-names>MA</given-names></name><name><surname>Thijsse</surname><given-names>A</given-names></name><name><surname>Throsby</surname><given-names>M</given-names></name><name><surname>Marissen</surname><given-names>WE</given-names></name><name><surname>Rood</surname><given-names>PM</given-names></name><name><surname>Bakker</surname><given-names>AB</given-names></name><name><surname>Gelderblom</surname><given-names>HR</given-names></name><name><surname>Martina</surname><given-names>BE</given-names></name><name><surname>Osterhaus</surname><given-names>AD</given-names></name><name><surname>Preiser</surname><given-names>W</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name><name><surname>de Kruif</surname><given-names>J</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name></person-group><year>2005</year><article-title>Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus</article-title><source>Journal of Virology</source><volume>79</volume><fpage>1635</fpage><lpage>1644</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.3.1635-1644.2005</pub-id><?supplied-pmid 15650189?><pub-id pub-id-type="pmid">15650189</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vennema</surname><given-names>H</given-names></name><name><surname>de Groot</surname><given-names>RJ</given-names></name><name><surname>Harbour</surname><given-names>DA</given-names></name><name><surname>Dalderup</surname><given-names>M</given-names></name><name><surname>Gruffydd-Jones</surname><given-names>T</given-names></name><name><surname>Horzinek</surname><given-names>MC</given-names></name><name><surname>Spaan</surname><given-names>WJ</given-names></name></person-group><year>1990</year><article-title>Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization</article-title><source>Journal of Virology</source><volume>64</volume><fpage>1407</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1128/JVI.64.3.1407-1409.1990</pub-id><?supplied-pmid 2154621?><pub-id pub-id-type="pmid">2154621</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>LM</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name></person-group><year>2018</year><article-title>Passive immunotherapy of viral infections: 'super-antibodies' enter the fray</article-title><source>Nature Reviews Immunology</source><volume>18</volume><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.148</pub-id><?supplied-pmid 29379211?><pub-id pub-id-type="pmid">29379211</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Wall</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name></person-group><year>2020</year><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><volume>181</volume><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><?supplied-pmid 32155444?><pub-id pub-id-type="pmid">32155444</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Tai</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Geng</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><year>2020</year><article-title>Molecular mechanism for antibody-dependent enhancement of coronavirus entry</article-title><source>Journal of Virology</source><volume>94</volume><fpage>e02015</fpage><lpage>e02019</lpage><pub-id pub-id-type="doi">10.1128/JVI.02015-19</pub-id><?supplied-pmid 31826992?><pub-id pub-id-type="pmid">31826992</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S-F</given-names></name><name><surname>Tseng</surname><given-names>S-P</given-names></name><name><surname>Yen</surname><given-names>C-H</given-names></name><name><surname>Yang</surname><given-names>J-Y</given-names></name><name><surname>Tsao</surname><given-names>C-H</given-names></name><name><surname>Shen</surname><given-names>C-W</given-names></name><name><surname>Chen</surname><given-names>K-H</given-names></name><name><surname>Liu</surname><given-names>F-T</given-names></name><name><surname>Liu</surname><given-names>W-T</given-names></name><name><surname>Chen</surname><given-names>Y-MA</given-names></name><name><surname>Huang</surname><given-names>JC</given-names></name></person-group><year>2014</year><article-title>Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins</article-title><source>Biochemical and Biophysical Research Communications</source><volume>451</volume><fpage>208</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.07.090</pub-id><pub-id pub-id-type="pmid">25073113</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Kuwahara</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Morioka</surname><given-names>H</given-names></name><name><surname>Sakaguchi</surname><given-names>N</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name></person-group><year>2016</year><article-title>Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in Non-human primates</article-title><source>ACS Infectious Diseases</source><volume>2</volume><fpage>361</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.6b00006</pub-id><?supplied-pmid 27627203?><pub-id pub-id-type="pmid">27627203</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wec</surname><given-names>AZ</given-names></name><name><surname>Bornholdt</surname><given-names>ZA</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Herbert</surname><given-names>AS</given-names></name><name><surname>Goodwin</surname><given-names>E</given-names></name><name><surname>Wirchnianski</surname><given-names>AS</given-names></name><name><surname>Gunn</surname><given-names>BM</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Abelson</surname><given-names>DM</given-names></name><name><surname>Moyer</surname><given-names>CL</given-names></name><name><surname>Jangra</surname><given-names>RK</given-names></name><name><surname>James</surname><given-names>RM</given-names></name><name><surname>Bakken</surname><given-names>RR</given-names></name><name><surname>Bohorova</surname><given-names>N</given-names></name><name><surname>Bohorov</surname><given-names>O</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Pauly</surname><given-names>MH</given-names></name><name><surname>Velasco</surname><given-names>J</given-names></name><name><surname>Bortz</surname><given-names>RH</given-names></name><name><surname>Whaley</surname><given-names>KJ</given-names></name><name><surname>Goldstein</surname><given-names>T</given-names></name><name><surname>Anthony</surname><given-names>SJ</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Walker</surname><given-names>LM</given-names></name><name><surname>Dye</surname><given-names>JM</given-names></name><name><surname>Zeitlin</surname><given-names>L</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Chandran</surname><given-names>K</given-names></name></person-group><year>2019</year><article-title>Development of a human antibody cocktail that deploys multiple functions to confer Pan-Ebolavirus protection</article-title><source>Cell Host &#x00026; Microbe</source><volume>25</volume><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2018.12.004</pub-id><?supplied-pmid 30629917?><pub-id pub-id-type="pmid">30629917</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>W&#x000f6;lfel</surname><given-names>R</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Guggemos</surname><given-names>W</given-names></name><name><surname>Seilmaier</surname><given-names>M</given-names></name><name><surname>Zange</surname><given-names>S</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MA</given-names></name><name><surname>Niemeyer</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>TC</given-names></name><name><surname>Vollmar</surname><given-names>P</given-names></name><name><surname>Rothe</surname><given-names>C</given-names></name><name><surname>Hoelscher</surname><given-names>M</given-names></name><name><surname>Bleicker</surname><given-names>T</given-names></name><name><surname>Br&#x000fc;nink</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Ehmann</surname><given-names>R</given-names></name><name><surname>Zwirglmaier</surname><given-names>K</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Wendtner</surname><given-names>C</given-names></name></person-group><year>2020</year><article-title>Virological assessment of hospitalized patients with COVID-2019</article-title><source>Nature</source><volume>581</volume><fpage>465</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2196-x</pub-id><?supplied-pmid 32235945?><pub-id pub-id-type="pmid">32235945</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Goldsmith</surname><given-names>JA</given-names></name><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Abiona</surname><given-names>O</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name></person-group><year>2020</year><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><?supplied-pmid 32075877?><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>LSY</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xun</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><year>2020</year><article-title>Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.03.30.20047365</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>KM</given-names></name><name><surname>Chiueh</surname><given-names>TS</given-names></name><name><surname>Siu</surname><given-names>LK</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Peng</surname><given-names>MY</given-names></name><name><surname>Wan</surname><given-names>HL</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Hu</surname><given-names>BS</given-names></name><name><surname>Perng</surname><given-names>CL</given-names></name><name><surname>Lu</surname><given-names>JJ</given-names></name><name><surname>Chang</surname><given-names>FY</given-names></name></person-group><year>2005</year><article-title>Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital</article-title><source>Journal of Antimicrobial Chemotherapy</source><volume>56</volume><fpage>919</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1093/jac/dki346</pub-id><?supplied-pmid 16183666?><pub-id pub-id-type="pmid">16183666</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>MK</given-names></name></person-group><year>2019</year><article-title>The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles</article-title><source>Human Vaccines &#x00026; Immunotherapeutics</source><volume>15</volume><fpage>2060</fpage><lpage>2065</lpage><pub-id pub-id-type="doi">10.1080/21645515.2019.1621148</pub-id><?supplied-pmid 31116633?><pub-id pub-id-type="pmid">31116633</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Yi</surname><given-names>CE</given-names></name><name><surname>Ba</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><name><surname>Ho</surname><given-names>D</given-names></name></person-group><year>2006</year><article-title>Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals</article-title><source>Journal of Medical Virology</source><volume>78</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/jmv.20499</pub-id><?supplied-pmid 16299724?><pub-id pub-id-type="pmid">16299724</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year>2020</year><article-title>Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection</article-title><source>Chest</source><volume>S0012-3692</volume><fpage>30571</fpage><lpage>30577</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2020.03.039</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Monteil</surname><given-names>VM</given-names></name><name><surname>Maurer-Stroh</surname><given-names>S</given-names></name><name><surname>Yew</surname><given-names>CW</given-names></name><name><surname>Leong</surname><given-names>C</given-names></name><name><surname>Mohd-Ismail</surname><given-names>NK</given-names></name><name><surname>Arularasu</surname><given-names>SC</given-names></name><name><surname>Chow</surname><given-names>VTK</given-names></name><name><surname>Rlt</surname><given-names>P</given-names></name><name><surname>Mirazimi</surname><given-names>A</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>Y-J</given-names></name></person-group><year>2020</year><article-title>Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.03.06.980037</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name></person-group><year>2020</year><article-title>Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2</article-title><source>International Journal of Biological Sciences</source><volume>16</volume><fpage>1718</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.7150/ijbs.45123</pub-id><?supplied-pmid 32226289?><pub-id pub-id-type="pmid">32226289</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Chakraborti</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Sheahan</surname><given-names>T</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Hensley</surname><given-names>LE</given-names></name><name><surname>Prabakaran</surname><given-names>P</given-names></name><name><surname>Rockx</surname><given-names>B</given-names></name><name><surname>Sidorov</surname><given-names>IA</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Vogel</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>JO</given-names></name><name><surname>Wang</surname><given-names>LF</given-names></name><name><surname>Baric</surname><given-names>R</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Curtis</surname><given-names>KM</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Dimitrov</surname><given-names>DS</given-names></name></person-group><year>2007</year><article-title>Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies</article-title><source>PNAS</source><volume>104</volume><fpage>12123</fpage><lpage>12128</lpage><pub-id pub-id-type="doi">10.1073/pnas.0701000104</pub-id><?supplied-pmid 17620608?><pub-id pub-id-type="pmid">17620608</pub-id></element-citation></ref></ref-list></back></article>